SDGR News and Press, Schrodinger Inc. From 02/14/24

Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its fourth quarter and full-year 2023 financial results on Wednesday, February 28, 2024, after the financial markets close. The company will h...

2024-01-22 01:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-11 09:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-11 08:30:00 ET Summary GoodRx Holdings announced preliminary financial results for Q4 2023, exceeding guidance on the top line. The company's financial performance in previous quarters has been disappointing, with declining revenue and profitability metrics. Management...

2024-01-08 08:24:10 ET More on Schrödinger Schrodinger Appears To Be Losing Momentum Schrodinger: Attractive Risk-Reward Schrödinger Q3 2023 Earnings Call Transcript KeyBanc sees opportunity in tech-enabled drug discovery stocks Schrödi...

Announces Expanded Multi-Year Software Agreement with Lilly Continued Focus in 2024 on Advancing Science Underlying Platform, Driving Software Adoption and Progressing Proprietary Pipeline Schrödinger , Inc. (Nasdaq: SDGR), Schrödinger (Nasdaq: SDGR), whose physics...

2024-01-08 04:48:22 ET Summary Schrodinger has lost momentum compared to its peer group, and its share price is no longer leading the pack. All three of SDGR's revenue streams, including its proprietary drug pipeline and collaborative drug discovery, seem to be under pressure. ...

2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...

Qiming Venture Partners' Portfolio Company UBTech Listed on Hong Kong Stock Exchange PR Newswire UBTech is the first humanoid robot company to go public on HKEx Qiming is UBTech's early institutional investor, exclusively investing in its Series A round in 2015 UBTech'...

2023-12-26 13:19:21 ET More on AbCellera Biologics, Absci, etc. Exscientia Looks Promising In AI-Driven Drug Development AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platf...